Indacaterol vs placebo
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
- Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes onlyOR 0.81 [0.7, 0.94]7 studies · 4807 participantsHigh